Borba (2020)
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
10.1001/jamanetworkopen.2020.8857
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499
Treatment
Treatment for COVID-19 (High dosage chloroquine diphosphate vs. Low dosage chloroquine diphosphate)
COVID-19 (death)
Odds ratio: 3.600 (1.200-10.600) Univariate analysis

Brazil

Randomized clinical trial

Registry

121

hospitalized patients with severe respiratory syndrome secondary to SARS-CoV-2 infection, 81 were enrolled (41 [50.6%] to chloroquine diphosphate high dosage group and 40 [49.4%] to low-dosage group).

CloroCovid-19 was a parallel, double-masked, randomized, phase IIb clinical trial, which started on March 23, 2020, aiming to assess the safety and efficacy of CQ in the treatment of hospitalized patients with severe respiratory syndrome secondary to SARS-CoV-2 infection. Overall mean (SD) age of 51.1 (13.9) years and a predominance of men (60 [75.3%]). Hypertension (25 of 55 [45.5%]), alcohol use disorder (14 of 51 [27.5%]), and diabetes (14 of 55 [25.5%]) were the most frequent comorbidities. Older age (mean [SD] age, 54.7 [13.7] years vs 47.4 [13.3] years) and more heart disease (5 of 28 [17.9%] vs 0) were seen in the high-dose group.

Total

28 Day


COVID-19 (death)

11

Patients were allocated to receive high-dosage chloroquine diphosphate (CQ) (ie, 600 mg CQ twice daily for 10 days) or low-dosage CQ (ie, 450 mg twice daily on day 1 and once daily for 4 days).


Treatment

Treatment for COVID-19

Eligible participants were allocated at a 1:1 ratio to receive orally (or via nasogastric tube in case of orotracheal intubation) either high-dosage CQ (600 mg CQ; 4 × 150 mg tablets twice daily for 1

Low dosage chloroquine diphosphate

High dosage chloroquine diphosphate


Odds ratio

3.600 (1.200-10.600)

No

Yes

No

none


none

Average

Yes